COVID-19 Variants: Pfizer, Moderna Updates, and IDSA Media Briefing
Moderna and Pfizer provide updates on mRNA vaccines against variant B.1.1.7; Infectious Diseases Society of America holds media briefing on COVID-19 variants.
COVID19
COVID-19 Reporting System, CT Severity Score Are Effective Diagnostic Tools
The COVID-19 Reporting and Data System (CO-RADS) in combination with a CT severity score are easy to use diagnostic tools to guide clinicians in diagnosing COVID-19.
FDA Urges HCPs to Follow Authorized Dosing Schedules for COVID-19 Vaccines
Additional research from the vaccine manufacturers would be needed to support any changes to the dosing schedule.
WHO: Remdesivir, Hydroxychloroquine, Lopinavir, Interferon Ineffective for COVID-19
World Health Organization expert provided data on 4 repurposed antiviral drugs – remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a – and its use in patients hospitalized with COVID-19.
Pulmonary Embolism Does Not Increase Mortality in Critically Ill Patients With COVID-19
Critically ill patients with COVID-19 who experience concurrent pulmonary embolism do not have increased mortality compared with patients without pulmonary embolism.
Infants With COVID-19 May Present With Gastrointestinal Symptoms
Overall, only 2% of infants tested were positive for COVID-19, but one-third required hospitalization.
Controversy: Protecting People Who Use Drugs During COVID-19
Anna Lembke, MD, discusses how patients who use drugs are affected by the convergence of 2 public health emergencies – increasing overdose rates, and the COVID-19 pandemic – and addresses controversial solutions proposed by other investigators.
Moderna COVID-19 Vaccine Shows High Efficacy, Low Risk for Adverse Events
The mRNA-1273 vaccine, developed by Moderna and the NIH, was evaluated for its efficacy in preventing COVID-19 illness with onset at least 14 days after the second injection.
Factors Contributing to Increased COVID-19 Risk in Blacks, Hispanics With Chronic Liver Diseases
A team of investigators sought to determine the impact of social and economic inequities on racial and ethnic minority individuals with chronic liver disease and COVID-19.
COVID-19 Antibodies Likely Protect From Reinfection for Up to 120 Days
Norman Sharpless, MD, director of the NCI, presented new findings on how prior infections with SARS-CoV-2 may have some degree of presentation against being reinfected with the virus.
-
Loading...
-
Loading...
Next post in COVID19
